Phathom Pharmaceuticals, Inc. — Form SCHEDULE 13D/A
Filed November 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Multiple Frazier Life Sciences funds (Public Fund, IX, X, XI, XII) and related entities, along with individuals James N. Topper and Patrick J. Heron, executed a joint filing agreement dated November 2, 2026, pursuant to SEC Rule 13d-1(k)(1). This permits a single Schedule 13G filing to cover their collective ownership of Phathom common stock. The document provides no disclosure of share count, ownership percentage, acquisition price, or changes to existing positions.
Why this rating
Joint filing agreement is routine administrative procedure; no ownership data, price, or position change disclosed. Cannot assess materiality without shareholding percentages or dollar amounts.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.